Business Insider

Samumed Presents Positive Preclinical Data on SM07883 at 2018 Alzheimer’s Association International Conference® (AAIC®)

Data supports SM07883 as a potential treatment for chronic tauopathies such as Alzheimer’s disease Company expects SM07883 to enter first-in-man studies in fall 2018 SAN DIEGO, July 27, 2018 (GLOBE ...
Business Insider

Samumed’s Osteoarthritis and Tendinopathy Research Selected for Multiple Presentations at the 2018 Osteoarthritis Research Society International (OARSI) World Congress

SAN DIEGO, April 23, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, a leader in Wnt research and development, today announced it will present its most recent clinical and preclinical data on the company’s ...
Business Wire

Samumed Presents Data for Potential Topical Treatment for Psoriasis

SAN DIEGO--(BUSINESS WIRE)--Samumed presented at the 2016 American College of Rheumatology (ACR) Annual Meeting preclinical results from in vitro and in vivo studies regarding the use of its small ...
Business Wire

Osteoarthritis (“OA”) Patients Face Higher Costs, According to Samumed and IHS Markit

SAN DIEGO--(BUSINESS WIRE)--Samumed, a leader in osteoarthritis research, and IHS Markit have jointly analyzed the health care resource use of Medicare patients with primary OA of the knee compared to ...
News Medical

Samumed to present preclinical and clinical data on Wnt pathway for OA treatment at ACR 2015

Samumed, LLC, a leader in tissue regeneration, announced today that it will present preclinical and clinical data on a small molecule modulator of the Wnt pathway (SM04690, an investigational new drug ...
BioWorld

Samumed raises $438M in equity round

Samumed LLC, a small company developing drugs to harness the Wnt pathway to treat multiple conditions, has closed a $438 million equity round at what it said was a pre-money valuation of $12 billion, ...